APA Citatie

Leurs, C. E., van Kempen, Z. L., Dekker, I., Balk, L. J., Wattjes, M. P., Rispens, T., . . . Killestein, J. (2017). Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients. Mult Scler.

Chicago Style citaat

Leurs, Cyra E., Zoé LE van Kempen, Iris Dekker, Lisanne J. Balk, Mike P. Wattjes, Theo Rispens, Bernard MJ Uitdehaag, en Joep Killestein. "Switching Natalizumab to Fingolimod Within 6 Weeks Reduces Recurrence of Disease Activity in MS Patients." Mult Scler 2017.

MLA citatie

Leurs, Cyra E., et al. "Switching Natalizumab to Fingolimod Within 6 Weeks Reduces Recurrence of Disease Activity in MS Patients." Mult Scler 2017.